Mizuho Upgrades LifeMD to Outperform, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 93.8%

Neg 0% Neu 0% Pos 93.8%

Mizuho analyst Steven Valiquette upgrades LifeMD (NASDAQ:LFMD) from Neutral to Outperform and raises the price target from $6 to $8.